Discover nano2026ReviewNon-viral Gene DeliveryDrug Delivery
Aadil Kr, Bhange K, Kommineni N, Mishra G, Bunekar N, Jha A, Et Al.
Messenger RNA (mRNA)-based therapeutics have transformed cancer treatment strategies, especially after the success of lipid nanoparticle (LNP)-enabled mRNA vaccines. LNPs are effective non-viral delivery vehicles that protect mRNA, enhance intracellular delivery, and improve therapeutic safety. This review discusses…
Read the article →Advances in pharmacological and pharmaceutical sciences2026ReviewNon-viral Gene DeliveryDrug Delivery
Abudayah Aa
Mucin, a highly glycosylated macromolecular component of mucus, has traditionally been regarded as a biological barrier that restricts drug transport across mucosal surfaces. Growing evidence, however, has repositioned mucin as a functional and engineerable biomaterial with distinctive potential for advanced drug…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Hari M, Subramony A, Dwivedi D, Krishnan Rs, Damodaran A, Nair Sc
Treatment for Parkinson's disease (PD) faces two significant challenges: first, the blood-brain barrier (BBB) and second, a therapeutic strategy that alleviates symptoms instead of stopping the disease progression. The BBB prevents over 98% of small-molecule drugs, leaving neuroprotective options mostly inaccessible…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Ainurofiq A, Rosalin Ea, Istiyono Ms, Maharani Na, Fauzy R, Sugiharti Sn, Et Al.
Chronic Obstructive Pulmonary Disease (COPD) is a condition that poses major challenges in therapeutic management, primarily due to the limitations of conventional inhalation methods in achieving optimal drug deposition and maintaining therapeutic effects over a long period. Inhalable nanomedicine has emerged as an…
Read the article →Current opinion in neurology2026ReviewDrug Delivery
Nakhate V, Wen Py
Drug delivery across the blood-brain barrier (BBB) remains an important challenge in the treatment of brain tumors. This review summarizes the physiologic barriers to effective CNS drug exposure and evaluates strategies to improve delivery, with a focus on glioma. Recent advances span three complementary approaches…
Read the article →Frontiers in immunology2026ReviewDrug Delivery
Di Domenico O, Marrapodi Mm, Di Feo G, Argenziano L, Rossi F, Di Paola A
Pediatric immune thrombocytopenia (ITP) is an acquired immune-mediated disorder triggered by autoantibody production directed against glycoproteins on the platelet surface, leading to platelet destruction in the spleen and impaired megakaryopoiesis in the bone marrow. The immune response is further compromised by a…
Read the article →Cardiovascular therapeutics2026ReviewDrug Delivery
Sivanathan B, Bobbala S, Venkatesh S
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, yet most therapies lack cardiovascular tissue- and cell-specificity, limiting efficacy and increasing off-target toxicity. Nanoparticle-based drug delivery systems offer opportunities to enhance myocardial targeting, improve…
Read the article →Molecular medicine reports2026ReviewDrug Delivery
Liu H, Yan H, Liu S, Xue Y, Huang J, Li S
Graphene‑based nanomaterials have emerged as a versatile platform for tumour‑targeted drug delivery owing to their unique physicochemical properties, including large specific surface area, structural flexibility and tuneable surface chemistry. Graphene oxide (GO) and reduced GO have been extensively investigated as…
Read the article →Exploration (Beijing, China)2026ReviewDrug Delivery
Lin Yj, Komperda I
Although nanomedicines offer advanced formulation control and physicochemical characterization, clinical translation has been limited. Delivery meta-analyses and late-stage attrition indicate biological validation is often a bottleneck. It must account for context-dependent processes such as protein corona formation…
Read the article →Discover nano2026ReviewDrug Delivery
Guan X, Hou X, Meng W, Guo Hd
Extracellular vesicles have garnered significant attention in the biomedical field due to their potential as therapeutic agents and diagnostic tools. Bovine milk extracellular vesicles (BMEVs), in particular, have emerged as a promising tool in biomedical research due to their unique biocompatibility, stability, and…
Read the article →European journal of medicinal chemistry2026ReviewDrug Delivery
Alahmary La, Sukkarieh Fa, Ferdous Ut, Helal A, Uddin S
Metal-organic frameworks (MOFs) are tuneable porous platforms for cancer drug delivery, as their metal nodes, organic linkers, pore architecture, and surface chemistry can be engineered to control cargo loading, targeting, degradation, and stimulus-responsive release. This review critically discusses the…
Read the article →Molecules (Basel, Switzerland)2026ReviewDrug Delivery
Lee M, Choi Y, Yoon Sj, Kim M
Extracellular vesicles (EVs) have emerged as promising therapeutic carriers owing to their biocompatibility, low immunogenicity, and ability to transport diverse biological cargo. However, successful EV-based therapy depends not only on carrier engineering but also on selecting an administration route appropriate for…
Read the article →Pharmaceutics2026ReviewDrug Delivery
Ban M, Zhao S, Liu Z, Zhao L
Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the…
Read the article →International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery
Thalij Km, You Hw, Habeeb M, Ratchagar Jv, Khot Vs, Gorde Pl
Hepatocellular carcinoma is the sixth most common cancer worldwide and a leading cause of cancer related mortality. Risk factors include chronic hepatitis B/C, obesity, alcohol abuse, diabetes and metabolic disorders. In advanced stages, normal treatments such as surgery, transplantation and chemotherapy are not as…
Read the article →Small2025ReviewNon-viral Gene DeliveryDrug Delivery
S Sarmah, S Baidya, M De
This review surveys lipid nanoparticle composition, ionisable lipid synthesis and strategies to target delivery of fragile RNA therapeutics while addressing tissue selectivity and immune activation.
Read the article →Advanced Science.2022ReviewDrug Delivery
De R, Mahata Mk, Kim K-T
Drug carriers are as important as drugs themselves, but clinical translation of polymeric nanocarriers (PNCs) remains limited by incomplete understanding of how carrier architecture and physicochemical properties affect loading, circulation, targeting, and release. The review addresses this gap by systematically…
Read the article →Stem Cell Research & Therapy2021ReviewNon-viral Gene Delivery
Farough Marofi, Roza Motavalli, Vladimir A. Safonov, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Markov Alexander, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Mostafa Jarahian, Sepideh Izadi, Ali Hassanzadeh, Naghmeh Shirafkan, Safa Tahmasebi, Farhad Motavalli Khiavi
CAR T cell therapy has transformed treatment of hematologic malignancies, but its efficacy in solid tumours remains unsupported. Solid tumours present distinct barriers—antigen heterogeneity, poor T cell trafficking/infiltration, and an immunosuppressive tumour microenvironment (TME)—that limit CAR T cell function…
Read the article →Blood Cancer Journal2021ReviewNon-viral Gene Delivery
Robert C. Sterner, Rosalie M. Sterner
CAR-T cell therapy has produced remarkable clinical responses in certain B cell leukemias and lymphomas, but major limitations remain—including life-threatening toxicities, limited efficacy in solid tumours, antigen escape, poor persistence/trafficking, and an immunosuppressive microenvironment. This review addresses…
Read the article →Advanced Functional Materials2021ReviewNon-viral Gene Delivery
Zhaoting Li, Yixin Wang, Yingyue Ding, Lauren Repp, Glen S. Kwon, Quanyin Hu
Immunotherapy has limited response rates and systemic side effects, and synthetic drug delivery systems can be immunogenic and toxic. Cell-based delivery systems—using endogenous cells as natural carriers—offer low immunogenicity, low toxicity, improved biocompatibility, active tissue targeting, and the ability to…
Read the article →Chemical Society Reviews* (as indicated by review format; exact volume/pages and DOI not included in the supplied file)2021ReviewNon-viral Gene Delivery
Yingshu Guo, Xiuping Cao, Xiaofei Zheng, Sk Jahir Abbas, Juan Li, Weihong Tan
Cancer treatment still relies heavily on chemotherapy, which causes severe damage to normal cells and systemic side effects. Safer, more selective drug delivery strategies are needed. Nanocarriers based on nucleic acids (NCNAs) are attractive because nucleic acids offer biocompatibility, low toxicity, programmable…
Read the article →Nature Reviews Drug Discovery2021ReviewDrug Delivery
Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas, Robert Langer
Nanoparticle (NP) research has generated promising preclinical results, but clinical translation remains limited. A major barrier is the mismatch between one-size-fits-all NP designs and the heterogeneous biological barriers across patients and diseases. Precision medicine offers patient stratification, but precision…
Read the article →ACS Nano2021ReviewDrug Delivery
Paula M. Cevaal, Abdalla Ali, Ewa Czuba-Wojnilowicz, Jori Symons, Sharon R. Lewin, Christina Cortez-Jugo, Frank Caruso
T cells are attractive targets for immunotherapy, cancer, HIV, autoimmunity, and inflammation, but nanoparticle delivery to T cells remains a major technological challenge due to their nonphagocytic nature and multiple physiological barriers. There is a need for rational design principles for in vivo T cell-targeting…
Read the article →Nature Reviews Materials2021ReviewDrug Delivery
Mandana T. Manzari, Yosi Shamay, Hiroto Kiguchi, Neal Rosen, Maurizio Scaltriti, And Daniel A. Heller
Precision medicine has transformed cancer therapy by enabling molecular profiling and optimised drug design, but clinical translation of many precision therapeutics is hindered by pharmacological limitations, including toxicities and drug resistance. Drug delivery materials can modulate a drug’s pharmacokinetics…
Read the article →APL Bioengineering2021ReviewNon-viral Gene Delivery
Matthew R. Aronson, Scott H. Medina, Michael J. Mitchell
Most clinically approved cancer therapies are potent and toxic small molecules limited by severe off-target toxicities and poor tumour-specific localisation. Liposomal encapsulation reduces toxicity, but reliance on passive targeting via the enhanced permeability and retention (EPR) effect leaves unresolved issues…
Read the article →